1. Opening Hook
While most Indian midcaps were busy blaming demand, geopolitics, and Mercury retrograde, Shaily Engineering Plastics casually delivered a quarter that looked like a PowerPoint fantasy. Revenues jumped, margins went vertical, and profits behaved like they’d just discovered steroids.
Healthcare, once a “nice optionality,” has now walked into the room, kicked the sofa aside, and taken control of the house. Consumer? Still there, sipping tea quietly. Industrial? Showing up on time. But GLP-1 pens? They’re clearly running the show.
Management sounded confident, bordering on smug, yet carefully avoided the “guidance” word like it’s radioactive. Canada approvals, semaglutide timelines, Chinese competition—everything was addressed, nothing panicked.
Stick around. The numbers look clean now, but the real drama is hidden inside capacity math, launch timing, and how much of this party is repeatable.
2. At a Glance
- Revenue up 34% – Healthcare finally stopped warming up and started sprinting.
- EBITDA doubled – From ₹41 cr to ₹82 cr; operating leverage woke up angry.
- EBITDA margin at 31.8% – Expanded 1,030 bps; cost discipline met product mix heaven.
- PAT up 134% – Profits didn’t just grow, they showed off.
- Healthcare revenue up 163% – From side quest to main storyline.
- Exports at 68% – India-made pens, global diabetes problems.
3. Management’s Key Commentary
“We delivered strong revenue growth of 34% with EBITDA margins expanding by over 1,000 basis points.”
(Translation: Everything worked at the same time. Please clap.) 😏
“Healthcare segment grew 163% year-on-year to ₹98.6 crores.”
(Translation: Remember when Consumer was our core business? Cute times.)
“We are increasing pen capacity from 40 million to 80 million by end FY26.”
(Translation: Demand pipeline is full, machines are being bullied.)
“We have onboarded a majority of generic players for GLP-1.”
(Translation: If someone launches semaglutide, chances are we’re billing them.)
“We do not give guidance.”
(Translation: Numbers are volatile, expectations are dangerous.)
“Axiom Max has been very well received at global conferences.”
(Translation: Innovators are listening, but cheques come later.) 🚀
“Chinese competition exists, but scale is the
